^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aurimune (CYT-6091)

    i
    Other names: CYT-6091, CYT 6091, TNF-bound colloidal Gold
    Associations

    News

    Trials
    Company:
    CytImmune
    Drug class:
    TNFα modulator
    Associations

    News

    Trials
    almost4years
    Targeting poorly differentiated and anaplastic thyroid cancer microenvironment via TNF-α/TGF-β/LOX signaling to improve drug delivery and treatment efficacy (AACR 2022)
    We previously showed that the tumor microenvironment of poorly-differentiated (PDTC) and anaplastic thyroid cancer (ATC) can be selectively and effectively treated with nanomedicine carrying recombinant human Tumor Necrosis Factor α (TNFα)(CYT6091), resulting in vascular leakage, decreased IFP, and increased intratumoral concentration of paclitaxel in vivo. Moreover, TGF-β1 inhibition downregulates the protein levels of Smad3 molecules in thyroid cancer cells. TCGA database studies of thyroid cancer patient samples showed that SMAD3 positively correlated with TGFBR1 and LOX, suggesting the involvement of SMAD3 in TGF-β/LOX signaling in the TME.
    Clinical
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • LOX (Lysyl Oxidase) • SMAD3 (SMAD Family Member 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    paclitaxel • Aurimune (CYT-6091)